| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
1,770,000,000 |
| Market
Cap: |
292.83(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$132.51 - $182.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 560 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and Juvederm Collection; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon, Lupron, and Synthroid.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
80,031 |
461,916 |
540,416 |
831,596 |
| Total Sell Value |
$14,256,265 |
$81,646,316 |
$93,320,391 |
$138,453,569 |
| Total People Sold |
2 |
9 |
9 |
12 |
| Total Sell Transactions |
2 |
11 |
13 |
29 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roberts Rebecca B |
Director |
– • – |
2022-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,421 |
9,753 |
|
- |
|
| Alpern Robert J |
Director |
– • – |
2022-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,421 |
31,542 |
|
- |
|
| Meyer Melody B |
Director |
– • – |
2022-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,421 |
12,523 |
|
- |
|
| Stewart Jeffrey Ryan |
EVP, Chief Commercial Officer |
• – – |
2022-03-24 |
4 |
S |
$159.20 |
$4,408,375 |
D/D |
(27,690) |
60,941 |
|
12% |
|
| Stewart Jeffrey Ryan |
EVP, Chief Commercial Officer |
• – – |
2022-03-24 |
4 |
OE |
$58.88 |
$1,630,387 |
D/D |
27,690 |
88,631 |
|
- |
|
| Durkin Brian L |
VP, Controller |
• – – |
2022-03-09 |
4 |
S |
$150.00 |
$2,794,301 |
D/D |
(18,628) |
19,094 |
|
-1% |
|
| Durkin Brian L |
VP, Controller |
• – – |
2022-03-09 |
4 |
OE |
$79.02 |
$923,112 |
D/D |
11,682 |
37,722 |
|
- |
|
| Strom Carrie C |
SVP & Pres Global Allerg Aesth |
• – – |
2022-03-06 |
4 |
D |
$150.56 |
$53,449 |
D/D |
(355) |
43,773 |
|
- |
|
| Strom Carrie C |
SVP & Pres Global Allerg Aesth |
• – – |
2022-03-05 |
4 |
D |
$150.56 |
$67,451 |
D/D |
(448) |
44,128 |
|
- |
|
| Strom Carrie C |
SVP & Pres Global Allerg Aesth |
• – – |
2022-03-02 |
4 |
D |
$147.69 |
$119,629 |
D/D |
(810) |
44,576 |
|
- |
|
| Gosebruch Henry O |
EVP, Chief Strategy Officer |
• – – |
2022-03-01 |
4/A |
S |
$146.81 |
$3,682,189 |
I/I |
(25,000) |
53,500 |
|
- |
|
| Gosebruch Henry O |
EVP, Chief Strategy Officer |
• – – |
2022-03-01 |
4 |
S |
$146.81 |
$3,682,189 |
D/D |
(25,000) |
16,623 |
|
-4% |
|
| Richmond Timothy J. |
EVP, Chief HR Officer |
• – – |
2022-03-01 |
4 |
S |
$147.52 |
$3,918,769 |
D/D |
(26,432) |
13,837 |
|
-4% |
|
| Sorg Elaine K. |
SVP, US Commercial Operations |
• – – |
2022-03-01 |
4 |
S |
$147.59 |
$961,467 |
D/D |
(6,484) |
17,876 |
|
-4% |
|
| Stewart Jeffrey Ryan |
EVP, Chief Commercial Officer |
• – – |
2022-03-01 |
4 |
S |
$147.43 |
$3,185,599 |
D/D |
(21,488) |
60,941 |
|
-4% |
|
| Michael Robert A. |
Vice Chairman |
• – – |
2022-03-01 |
4 |
S |
$147.41 |
$6,390,247 |
D/D |
(43,105) |
37,877 |
|
-4% |
|
| Gosebruch Henry O |
EVP, Chief Strategy Officer |
• – – |
2022-03-01 |
4 |
S |
$147.54 |
$2,223,836 |
D/D |
(15,000) |
41,623 |
|
-4% |
|
| Durkin Brian L |
VP, Controller |
• – – |
2022-02-25 |
4 |
D |
$149.54 |
$1,134,859 |
D/D |
(7,589) |
26,040 |
|
- |
|
| Strom Carrie C |
SVP & Pres Global Allerg Aesth |
• – – |
2022-02-25 |
4 |
D |
$149.54 |
$424,694 |
D/D |
(2,840) |
45,386 |
|
- |
|
| Richmond Timothy J. |
EVP, Chief HR Officer |
• – – |
2022-02-25 |
4 |
D |
$149.54 |
$3,144,378 |
D/D |
(21,027) |
40,269 |
|
- |
|
| Hudson Thomas J |
SVP, R&D and CSO |
• – – |
2022-02-25 |
4 |
D |
$149.54 |
$2,005,032 |
D/D |
(13,408) |
46,228 |
|
- |
|
| Sorg Elaine K. |
SVP, US Commercial Operations |
• – – |
2022-02-25 |
4 |
D |
$149.54 |
$1,663,633 |
D/D |
(11,125) |
24,360 |
|
- |
|
| Saleki-Gerhardt Azita |
EVP, Operations |
• – – |
2022-02-25 |
4 |
D |
$149.54 |
$3,306,030 |
D/D |
(22,108) |
157,912 |
|
- |
|
| Severino Michael |
Vice Chairman |
• – – |
2022-02-25 |
4 |
D |
$149.54 |
$5,810,676 |
D/D |
(38,857) |
152,103 |
|
- |
|
| Stewart Jeffrey Ryan |
EVP, Chief Commercial Officer |
• – – |
2022-02-25 |
4 |
D |
$149.54 |
$2,556,087 |
D/D |
(17,093) |
82,429 |
|
- |
|
765 Records found
|
|
Page 7 of 31 |
|
|
3.30 (2.04%) 
